Cargando…

Dosimetry verification of 3D-printed individual template based on CT-MRI fusion for radioactive (125)I seed implantation in recurrent high-grade gliomas

PURPOSE: To verify the accuracy and efficacy of three-dimensional printing individual template (3D-PIT) with computed tomography-magnetic resonance imaging (CT-MRI) fusion for radioactive iodine-125 ((125)I) seed implantation in high-grade brain gliomas. MATERIAL AND METHODS: Between June 2017 and J...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Shifeng, Wang, Hong, Wang, Congxiao, Zhang, Hao, Li, Wei, Dong, Qian, Hu, Xiaokun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701383/
https://www.ncbi.nlm.nih.gov/pubmed/31435430
http://dx.doi.org/10.5114/jcb.2019.85729
_version_ 1783445046434988032
author Liu, Shifeng
Wang, Hong
Wang, Congxiao
Zhang, Hao
Li, Wei
Dong, Qian
Hu, Xiaokun
author_facet Liu, Shifeng
Wang, Hong
Wang, Congxiao
Zhang, Hao
Li, Wei
Dong, Qian
Hu, Xiaokun
author_sort Liu, Shifeng
collection PubMed
description PURPOSE: To verify the accuracy and efficacy of three-dimensional printing individual template (3D-PIT) with computed tomography-magnetic resonance imaging (CT-MRI) fusion for radioactive iodine-125 ((125)I) seed implantation in high-grade brain gliomas. MATERIAL AND METHODS: Between June 2017 and June 2018, 16 patients with recurrent high-grade gliomas (rHGG) underwent radioactive seed implantation with 3D-PIT. The prescribed dose was 120-140 Gy. We compared the dose distribution of the postoperative plan with the preoperative plan. Dose parameters included D(90), V(100), V(200), conformity index (CI), and external index of the target volume (EI). Local control and early complications were also analyzed. RESULTS: Sixteen treatment areas were reported in our study. Median gross tumor volume (preoperative) of patients was 64.2 cm(3), median needle number was 8, and median number of implanted (125)I seeds was 60. For postoperative plans, the median D(90), V(100), and V(200) was 152.1 Gy, 96.8%, and 49.1%, respectively, and 151.7 Gy, 97.0%, and 48.9%, respectively, in preoperative plans. Comparing with the preplanned cases, the dose of the target volume was slightly higher; the high-dose area of the target volume was larger in postoperative cases, but the difference was not statistically significant (p > 0.05). Actual dose conformity of the target volume was greater than preplanned, and the difference was not statistically significant (p > 0.05). Local control was 81.25% and 75% at 3 and 6 months after implantation, respectively. No serious early toxicities were observed. CONCLUSIONS: 3D-PIT based on the CT-MRI fusion images can result in good accuracy for positioning and dose distribution in radioactive seed implantation for treatment of rHGG.
format Online
Article
Text
id pubmed-6701383
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-67013832019-08-21 Dosimetry verification of 3D-printed individual template based on CT-MRI fusion for radioactive (125)I seed implantation in recurrent high-grade gliomas Liu, Shifeng Wang, Hong Wang, Congxiao Zhang, Hao Li, Wei Dong, Qian Hu, Xiaokun J Contemp Brachytherapy Original Paper PURPOSE: To verify the accuracy and efficacy of three-dimensional printing individual template (3D-PIT) with computed tomography-magnetic resonance imaging (CT-MRI) fusion for radioactive iodine-125 ((125)I) seed implantation in high-grade brain gliomas. MATERIAL AND METHODS: Between June 2017 and June 2018, 16 patients with recurrent high-grade gliomas (rHGG) underwent radioactive seed implantation with 3D-PIT. The prescribed dose was 120-140 Gy. We compared the dose distribution of the postoperative plan with the preoperative plan. Dose parameters included D(90), V(100), V(200), conformity index (CI), and external index of the target volume (EI). Local control and early complications were also analyzed. RESULTS: Sixteen treatment areas were reported in our study. Median gross tumor volume (preoperative) of patients was 64.2 cm(3), median needle number was 8, and median number of implanted (125)I seeds was 60. For postoperative plans, the median D(90), V(100), and V(200) was 152.1 Gy, 96.8%, and 49.1%, respectively, and 151.7 Gy, 97.0%, and 48.9%, respectively, in preoperative plans. Comparing with the preplanned cases, the dose of the target volume was slightly higher; the high-dose area of the target volume was larger in postoperative cases, but the difference was not statistically significant (p > 0.05). Actual dose conformity of the target volume was greater than preplanned, and the difference was not statistically significant (p > 0.05). Local control was 81.25% and 75% at 3 and 6 months after implantation, respectively. No serious early toxicities were observed. CONCLUSIONS: 3D-PIT based on the CT-MRI fusion images can result in good accuracy for positioning and dose distribution in radioactive seed implantation for treatment of rHGG. Termedia Publishing House 2019-06-28 2019-06 /pmc/articles/PMC6701383/ /pubmed/31435430 http://dx.doi.org/10.5114/jcb.2019.85729 Text en Copyright: © 2019 Termedia Sp. z o. o. http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Original Paper
Liu, Shifeng
Wang, Hong
Wang, Congxiao
Zhang, Hao
Li, Wei
Dong, Qian
Hu, Xiaokun
Dosimetry verification of 3D-printed individual template based on CT-MRI fusion for radioactive (125)I seed implantation in recurrent high-grade gliomas
title Dosimetry verification of 3D-printed individual template based on CT-MRI fusion for radioactive (125)I seed implantation in recurrent high-grade gliomas
title_full Dosimetry verification of 3D-printed individual template based on CT-MRI fusion for radioactive (125)I seed implantation in recurrent high-grade gliomas
title_fullStr Dosimetry verification of 3D-printed individual template based on CT-MRI fusion for radioactive (125)I seed implantation in recurrent high-grade gliomas
title_full_unstemmed Dosimetry verification of 3D-printed individual template based on CT-MRI fusion for radioactive (125)I seed implantation in recurrent high-grade gliomas
title_short Dosimetry verification of 3D-printed individual template based on CT-MRI fusion for radioactive (125)I seed implantation in recurrent high-grade gliomas
title_sort dosimetry verification of 3d-printed individual template based on ct-mri fusion for radioactive (125)i seed implantation in recurrent high-grade gliomas
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701383/
https://www.ncbi.nlm.nih.gov/pubmed/31435430
http://dx.doi.org/10.5114/jcb.2019.85729
work_keys_str_mv AT liushifeng dosimetryverificationof3dprintedindividualtemplatebasedonctmrifusionforradioactive125iseedimplantationinrecurrenthighgradegliomas
AT wanghong dosimetryverificationof3dprintedindividualtemplatebasedonctmrifusionforradioactive125iseedimplantationinrecurrenthighgradegliomas
AT wangcongxiao dosimetryverificationof3dprintedindividualtemplatebasedonctmrifusionforradioactive125iseedimplantationinrecurrenthighgradegliomas
AT zhanghao dosimetryverificationof3dprintedindividualtemplatebasedonctmrifusionforradioactive125iseedimplantationinrecurrenthighgradegliomas
AT liwei dosimetryverificationof3dprintedindividualtemplatebasedonctmrifusionforradioactive125iseedimplantationinrecurrenthighgradegliomas
AT dongqian dosimetryverificationof3dprintedindividualtemplatebasedonctmrifusionforradioactive125iseedimplantationinrecurrenthighgradegliomas
AT huxiaokun dosimetryverificationof3dprintedindividualtemplatebasedonctmrifusionforradioactive125iseedimplantationinrecurrenthighgradegliomas